Literature DB >> 12776266

A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children.

Masahiro Hiraoka1, Hirokazu Tsukahara, Kousaku Matsubara, Masahito Tsurusawa, Nobuaki Takeda, Shinichi Haruki, Shuhei Hayashi, Kazuhide Ohta, Tohru Momoi, Yusei Ohshima, Narufumi Suganuma, Mitsufumi Mayumi.   

Abstract

BACKGROUND: Long-course prednisolone regimens have been shown to be more effective than short-course regimens in sustaining remission of nephrotic syndrome in children. However, the most beneficial approach among the long-course regimens remains unknown.
METHODS: Seventy-three children with new-onset nephrotic syndrome were allocated at random to the two long-course regimens and followed up for 2 years. Group A was administered prednisolone at a daily dose of 60 mg/m2 for 6 weeks, followed by an alternate-day dose of 40 mg/m2 for 6 weeks (the long daily regimen). Group B was administered the same daily dose for 4 weeks, followed by an alternate-day dose of 60 mg/m2 for 4 weeks, and doses were tapered by 10 mg/m2 every 4 weeks (the long alternate-day regimen).
RESULTS: Group B had a lower incidence of corticosteroid toxicities than group A during the initial treatment. Kaplan-Meier analysis of the sustained remission rate of the two treatment groups showed a marginally significant difference (P = 0.069) and showed a significant difference when patients were stratified for age of disease onset (P = 0.048). In a subgroup of younger children (<4 years at onset), group B had a greater rate of sustained remission (P < 0.01) and fewer children with frequent relapses (P < 0.05) than group A, whereas in older children (> or =4 years at onset), both groups had similar good sustained remission rates.
CONCLUSION: These findings collectively indicate that the long alternate-day regimen may be more beneficial, with less corticosteroid toxicities, than the long daily regimen, and children with younger age at disease onset may be susceptible to relapse and especially benefit from the long alternate-day regimen for sustaining remission of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12776266     DOI: 10.1016/s0272-6386(03)00346-9

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  27 in total

1.  Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial.

Authors:  Vaishnavi Raman; Sriram Krishnamurthy; K T Harichandrakumar
Journal:  Pediatr Nephrol       Date:  2016-01-12       Impact factor: 3.714

2.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

3.  A novel genotyping method for detection of the CRHR1 (rs1396862: C>T) gene variation among North Indian population.

Authors:  Neeraj Sharma; Shally Awasthi; Subha R Phadke
Journal:  Mol Biol Rep       Date:  2014-01-23       Impact factor: 2.316

Review 4.  New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome.

Authors:  Michael van Husen; Markus J Kemper
Journal:  Pediatr Nephrol       Date:  2011-01-13       Impact factor: 3.714

5.  Corticosteroids for the initial episode of steroid-sensitive nephrotic syndrome.

Authors:  Elisabeth M Hodson; Deirdre Hahn; Jonathan C Craig
Journal:  Pediatr Nephrol       Date:  2015-04-26       Impact factor: 3.714

Review 6.  Corticosteroid therapy for nephrotic syndrome in children.

Authors:  Deirdre Hahn; Elisabeth M Hodson; Narelle S Willis; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2015-03-18

7.  Five-year outcome of children with idiopathic nephrotic syndrome: the NEPHROVIR population-based cohort study.

Authors:  Claire Dossier; Jean-Daniel Delbet; Olivia Boyer; Patrick Daoud; Bettina Mesples; Beatrice Pellegrino; Helène See; Gregoire Benoist; Anne Chace; Anis Larakeb; Julien Hogan; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2018-12-14       Impact factor: 3.714

8.  Uncertainty in management of childhood-onset idiopathic nephrotic syndrome: is the long-term prognosis really favorable?

Authors:  Shuichiro Fujinaga; Amane Endo; Yoshiyuki Ohtomo; Yoshikazu Ohtsuka; Toshiaki Shimizu
Journal:  Pediatr Nephrol       Date:  2013-07-09       Impact factor: 3.714

9.  Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome.

Authors:  Nynke Teeninga; Joana E Kist-van Holthe; Nienske van Rijswijk; Nienke I de Mos; Wim C J Hop; Jack F M Wetzels; Albert J van der Heijden; Jeroen Nauta
Journal:  J Am Soc Nephrol       Date:  2013-01       Impact factor: 10.121

10.  C1q nephropathy and minimal change nephrotic syndrome.

Authors:  Craig S Wong; Christopher A Fink; Jane Baechle; Alexis A Harris; Amy O Staples; John R Brandt
Journal:  Pediatr Nephrol       Date:  2008-12-11       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.